Immune Design Corporation

116 articles about Immune Design Corporation

• Immune Design Corporation Reports Third Quarter 2014 Financial Results And Provides Corporate Update

  11/12/2014

• Immune Design Corporation To Report Third Quarter 2014 Financial Results And Provide Corporate Update

  11/5/2014

• Sanofi Pasteur And Immune Design Corporation Enter Broad Collaboration For The Development Of A Herpes Simplex Virus Therapy

  10/16/2014

• Immune Design Corporation Added To Russell 2000® Index

  10/2/2014

• Sanofi (France), Immune Design Corporation Strike Food Allergy Deal Worth $168 Million+

  8/7/2014

• Immune Design Corporation Announces Closing Of Initial Public Offering

  7/30/2014

• Immune Design Corporation Announces Filing Of New Lawsuit By Theravectys SA

  7/28/2014

• THERAVECTYS Files Suit In The U.S. Against Immune Design Corporation

  7/25/2014

• Seattle Biotech Immune Design Corporation Prices IPO At $12 Per Share, The Low End Of The Range

  7/24/2014

• Seattle's Immune Design Corporation Files For $60 Million IPO

  6/27/2014

• Immune Design Corporation Announces Treatment Of First Patient In Phase 1 Clinical Trial Of LV305 Immuno-Oncology Agent

  6/5/2014

• Immune Design Corporation's GLAAS™ Discovery Platform Used In MEDI7510 Phase 1 Trial For Respiratory Syncytial Virus

  5/27/2014

• Immune Design Corporation Appoints Franklin M. Berger To Board Of Directors

  3/18/2014

• Immune Design Corporation Announces Treatment Of First Patient In Phase 1 Clinical Trial Of ID-G305 Cancer Immunotherapy Agent

  2/27/2014

• Immune Design Corporation To Present At Upcoming Investor Conferences In February

  2/3/2014

• Immune Design Corporation Announces Treatment Of First Patient In Phase 1 Clinical Trial Of ID-G100, An Investigational Immuno-Oncology Agent

  1/27/2014

• Immune Design Corporation Lands $49 Million Series C; New Investors Include Drug Giant Sanofi (France) and Investment Firm SGBV

  10/30/2013

• Immune Design Corporation Appoints Frank J. Hsu, M.D., Vice President, Head of Oncology

  10/24/2013

• Immune Design Corporation Appoints Jan Henrik ter Meulen, M.D., Chief Scientific Officer

  10/1/2013

• Immune Design Corporation Appoints Stephen R. Brady Chief Business Officer

  9/26/2013